DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprostene bunod

First Posted Date: 2013-07-11

Last Posted Date: 2018-07-26

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 130

Registration Number: NCT01895972

Locations: 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Intraocular Pressure

Interventions: Drug: Latanoprostene bunod

First Posted Date: 2013-07-11

Last Posted Date: 2018-05-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 24

Registration Number: NCT01895985

Locations: 🇺🇸
Bausch & Lomb Incorporated, Madison, New Jersey, United States

A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Silicone Hydrogel Contact Lens

First Posted Date: 2013-06-10

Last Posted Date: 2019-07-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 400

Registration Number: NCT01873846

Locations: 🇺🇸
Bausch & Lomb Incorporated, Madison, New Jersey, United States

Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism

Not Applicable

Completed

Conditions: Astigmatism

Interventions: Device: enVista control lens
Device: enVista® One-Piece Hydrophobic Acrylic Toric IOL

First Posted Date: 2013-05-13

Last Posted Date: 2020-09-16

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 191

Registration Number: NCT01852084

Locations: 🇺🇸
Bausch & Lomb, Irvine, California, United States

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Phase 2

Completed

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: Lotemax
Drug: Soothe® Lubricant Eye Drops
Drug: Restasis

First Posted Date: 2013-03-25

Last Posted Date: 2019-08-30

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 102

Registration Number: NCT01817582

Locations: 🇺🇸
Bausch & Lomb Incorporated, Irvine, California, United States

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

Not Applicable

Withdrawn

Conditions: Dry Eye

Interventions: Device: Artelac Rebalance
Device: Vismed

First Posted Date: 2013-02-15

Last Posted Date: 2013-10-11

Lead Sponsor: Bausch & Lomb Incorporated

Registration Number: NCT01791426

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Bepotastine besilate
Drug: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 617

Registration Number: NCT01753739

Locations: 🇺🇸
Bausch & Lomb Incorporated, Irvine, California, United States

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: BOL-303259-X
Drug: Timolol

First Posted Date: 2012-12-17

Last Posted Date: 2018-11-07

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 420

Registration Number: NCT01749904

Locations: 🇺🇸
Bausch & Lomb Inc., Rochester, New York, United States

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: BOL-303259-X
Drug: Timolol

First Posted Date: 2012-12-17

Last Posted Date: 2018-11-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 420

Registration Number: NCT01749930

Locations: 🇺🇸
Bausch & Lomb Inc., Rochester, New York, United States

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Phase 3

Terminated

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle
Drug: Besifloxacin

First Posted Date: 2012-12-04

Last Posted Date: 2014-10-01

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 136

Registration Number: NCT01740388

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy